
A NOVEL INTRONIC SPLICE SITE TAFAZZIN GENE
MUTATION DETECTED PRENATALLY IN A FAMILY
WITH BARTH SYNDROME Bakšienė M, Benušienė E, Morkūnienė A, Ambrozaitytė L, Utkus A, Kučinskas V *Corresponding Author: Marija Bakšienė, M.D., Department of Human and Medical Genetics, Vilnius University,
Santarişkių Str. 2, LT-08861 Vilnius, Lithuania. Tel: +3702365116. E-mail: m.baksiene@gmail. com page: 95
|
INTRODUCTION
Barth syndrome (BTHS, OMIM 302060) is a rare
X-linked disease characterized by dilated cardiomyopathy,
proximal skeletal myopathy and cyclic neutropenia
and was first described in 1983 by Barth et al. [1]. The
incidence of BTHS is about 1 in 300,000-400,000 births
[2]. It is also presented with organic aciduria, particularly
excess of 3-methylglutaconic acid [1,3]. The excretion of
3-methylglutaconic acid in urine can be highly variable and
is often intermittent. At the moment, 3-methylglutaconic
acid is a biochemical marker for mitochondrial dysfunction
of still unknown origin [4]. Less common features of the
disease include hypertrophic cardiomyopathy, isolated left
ventricular noncompaction, ventricular arrhythmia, motor
delay, poor appetite, fatigue and exercise intolerance, hypoglycemia,
lactic acidosis, hyperammonemia and growth
delay [5,6]. The main cause of death in infants with BTHS
is either heart failure or sepsis due to neutropenia [1,2,5].
Barth syndrome is caused by various mutations in the
tafazzin (TAZ, previously termed G4.5) gene [7], comprising
11 exons and located on Xq28 [8,9]. This gene encodes
a protein tafazzin that plays an important role in remodelling
of cardiolipin and phosphatidylglycerol structure [1].
Cardiolipin is a component of the inner mitochondrial
membrane. It stabilizes highly ordered respiratory chain
supercomplexes and optimises energy production in mitochondria
[10]. Studies carried out on a BTHS zebrafish
model suggest that the expression of tafazzins is both
tissue-specific and age-dependent, and plays an essential
role in cardiac development and function [11,12]. We report
a novel splice site mutation in intron 3 of the TAZ
gene in this study.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|